NCT00587899

Brief Summary

This study is being done to learn the effects of the Pulmonary Vein Isolation in patients that are at high risk to developing, but do not have a documented history of atrial fibrillation.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
41

participants targeted

Target at below P25 for not_applicable atrial-fibrillation

Timeline
Completed

Started Jan 2007

Typical duration for not_applicable atrial-fibrillation

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2007

Completed
12 months until next milestone

First Submitted

Initial submission to the registry

December 22, 2007

Completed
17 days until next milestone

First Posted

Study publicly available on registry

January 8, 2008

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2009

Completed
Last Updated

April 14, 2011

Status Verified

April 1, 2011

Enrollment Period

2.8 years

First QC Date

December 22, 2007

Last Update Submit

April 12, 2011

Conditions

Keywords

Atrial FibrillationAFA fibcardiac ablationmodified maze procedure

Outcome Measures

Primary Outcomes (1)

  • Evaluated by the number of patients free of taking antiarrhythmic medications and free of AF as determined by a 24-hour Holter recording.

    12 months

Study Arms (2)

1

OTHER

The treatment group will undergo operation for mitral valve disease with an additional procedure called Pulmonary Vein Isolation.

Procedure: Pulmonary Vein Isolation

2

NO INTERVENTION

The control group of patients will undergo operation for mitral valve disease without the additional Pulmonary Vein Isolation

Interventions

The treatment group will undergo operation for mitral valve disease with an additional procedure called Pulmonary Vein Isolation using a device that delivers radiofrequency energy to the heart muscle in order to create scar tissue to block electrical impulses that can trigger episodes of AF.

1

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Indication for open-heart surgery: Mitral valve repair or replacement, evidence of a dilated left atrium

You may not qualify if:

  • History of Atrial Fibrillation
  • Need for emergent cardiac surgery
  • Previous cardiac surgery
  • Preoperative need for an intraaortic balloon pump or intravenous inotropes
  • Current diagnosis of active endocarditis
  • Mental impairment/or experience other conditions which may not allow subject to understand nature
  • Significance and scope of study
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mayo Clinic

Rochester, Minnesota, 55902, United States

Location

MeSH Terms

Conditions

Atrial Fibrillation

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Thoralf M. Sundt, III, M.D.

    Professor of Surgery, Mayo Clinic

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

December 22, 2007

First Posted

January 8, 2008

Study Start

January 1, 2007

Primary Completion

November 1, 2009

Study Completion

November 1, 2009

Last Updated

April 14, 2011

Record last verified: 2011-04

Locations